Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C

Villa, Erica; Karampatou, Aimilia; Cammà, Calogero; Leo, Alfredo Di; Luongo, Monica; Ferrari, Anna; Petta, Salvatore; Losi, Luisa; Taliani, Gloria; Trande, P.; Lei, Barbara; Graziosi, Amalia; Bernabucci, Veronica; Critelli, Rosina Maria; Pazienza, P.; Rendina, Maria; Antonelli, Alessandro; Francavilla, A.

doi:10.1053/j.gastro.2010.12.027

Cited by 101 publications

(92 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Steatosis showed a higher prevalence in chronic-HCV patients in post-menopause (> 55 years); moreover the pro-inflammation state related with menopause may cause a moderate to severe fibrosis progression, leading to an inefficient response to antiviral therapy. [12,13] In our sample, the pre-treatment steatosis level did not differ meaningfully in two genders either in the whole sample or in younger and older than 50 years groups. The presence of fibrosis at baseline was not associated to gender either in the overall sample or in two examinated groups.…”

Section: Discussioncontrasting

confidence: 46%

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Belci¹,

Collo²,

Martorana³

et al. 2016

View full text Add to dashboard Cite

Aim:The liver is a sexually dimorphic organ presenting gender differences in its metabolism, functions, enzyme activity, membrane lipid composition and immune response. This paper aimed to assess whether gender may predict virological response to standard antiviral therapy in subjects with chronic hepatitis C (CHC). Methods: The authors retrospectively analyzed 100 patients with genotype 1 CHC (55 men, 45 women), who performed standard antiviral therapy (interferon and ribavirin for 12 months) in the period 2002-2012, evaluated with blood tests and abdominal ultrasound to compare different virological and biochemical response in both gender. Results: Rate of substained virological response (SVR) was higher, but not significant, in women than men (46.7% vs. 34.5%, P = 0.05); difference became significant after stratification by age (< 50 and ≥ 50 years). Specifically in the group aged under 50 years, rate of SVR was significantly higher in women than in men (66.7% vs. 38.2%, P < 0.05). Conclusion: Female gender may predict virological response to standard antiviral therapy in subjects with CHC aged below 50 years. Considering new potent and more expensive antiviral drugs actually available for HCV treatment, it could be useful to identify candidates firstly eligible to therapy.

show abstract

Section: Discussioncontrasting

confidence: 46%

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Belci¹,

Collo²,

Martorana³

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, after menopause and the decreased of ovarian hormone production these cytokines levels could increase (8) . Villa et al (22) observed that the estrogens-deprived environment in PMW with chronic hepatitis C virus (CHC) had influence in progression to fibrosis. There are reports that estrogen inhibits the myofibroblastic transformation of rat stellate cells that are responsible for hyper secretion of collagen and fibrosis, pointing to a possible anti fibrotic effect of this drug (26) .…”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease in Menopausal Women

Florentino

Cotrim

Vilar

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Nonalcoholic Fatty Liver Disease (NAFLD) is common in postmenopausal women. It is associated with metabolic syndrome. However, the influence of hormone replacement therapy in NAFLD development in these women needs to be investigated. This study aimed to describe the clinical characteristics of NAFLD in postmenopausal women, and the relationship between hormone replacement therapy and this disease. (79/198) without hormone replacement therapy. Gamma-glutamyl transpeptidase (P = 0.001), alanine transaminase (P<0.01), ferritin (P<0.001) and insulin resistance (homeostatic model assessment of insulin resistance ≥3) (P<0.001) were higher in the group of women with NAFLD diagnosis who did not referred the use of hormone replacement therapy. Metabolic syndrome was also more frequent in women with NAFLD, who did not refer hormone replacement therapy. Conclusion -In conclusion this data suggests elevated prevalence of NAFLD in postmenopausal women; negative association of hormone replacement therapy and NAFLD. HEADINGS -Fatty Liver. Hormone replacement therapy.

show abstract

“…The sustained virological response (SVR) rate is significantly higher in women than in men, and women in fertile age with easy genotypes have a 100% chance of obtaining a SVR [ 89 ]. Data from another Italian study strongly suggest that early menopause is associated with a low likelihood of SVR, probably because of inflammatory factors that change at menopause [ 90 ]. Another explanation for the high rate of SVR in female patients in fertile age may be the effect of the depletion of iron as a result of menstruation.…”

Section: Chronic Hepatitis Cmentioning

confidence: 99%

Gender medicine: a task for the third millennium

Baggio

Corsini

Floreani

et al. 2013

Clinical Chemistry and Laboratory Medicine (CCLM)

183

127

View full text Add to dashboard Cite

Gender-specific medicine is the study of how diseases differ between men and women in terms of prevention, clinical signs, therapeutic approach, prognosis, psychological and social impact. It is a neglected dimension of medicine. In this review we like to point out some major issues in five enormous fields of medicine: cardiovascular diseases (CVDs), pharmacology, oncology, liver diseases and osteoporosis.CVDs have been studied in the last decades mainly in men, but they are the first cause of mortality and disability in women. Risk factors for CVD have different impacts in men and women; clinical manifestations of CVD and the influence of drugs on CVD have lot of gender differences. Sex-related differences in pharmacokinetics and pharmacodynamics are also emerging. These differences have obvious relevance to the efficacy and side effect profiles of various medications in the two sexes. This evidence should be considered for drug development as well as before starting any therapy. Gender disparity in cancer incidence, aggressiveness and prognosis has been observed for a variety of cancers and, even if partially known, is underestimated in clinical practice for the treatment of the major types of cancer. It is necessary to systematize and encode all the known data for each type of tumor on gender differences, to identify where this variable has to be considered for the purposes of the prognosis, the choice of treatment and possible toxicity. Clinical data suggest that men and women exhibit differences regarding the epidemiology and the progression of certain liver diseases , i.e., autoimmune conditions, genetic hemochromatosis, non-alcoholic steatohepatitis and chronic hepatitis C. Numerous hypotheses have been formulated to justify this sex imbalance including sex hormones, reproductive and genetic factors. Nevertheless, none of these hypothesis has thus far gathered enough convincing evidence and in most cases the evidence is conflicting. Osteoporosis is an important public health problem both in women and men. On the whole, far more epidemiologic, diagnostic and therapeutic studies have been carried out in women than in men. In clinical practice, if this disease remains underestimated in women, patients ' and physicians ' awareness is even lower for male osteoporosis, for which diagnostic and therapeutic strategies are at present less defined.In conclusion this review emphasizes the urgency of basic science and clinical research to increase our understanding of the gender differences of diseases.

show abstract

Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C

Cited by 101 publications

References 41 publications

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Nonalcoholic Fatty Liver Disease in Menopausal Women

Gender medicine: a task for the third millennium

Contact Info

Product

Resources

About